For Immediate Release Contact firstname.lastname@example.org
November 30, 2011
CHICAGO, Nov. 30, 2011 – Toshiba America Medical Systems, Inc. announces new functional-based clinical applications – Dual Energy and Myocardial Perfusion (both works-in-progress), as well as Body Perfusion – for its AquilionTM CT systems. These applications are shown at this year’s Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 27 – Dec. 2, 2011 (Booth #5634, South Hall).
Dual Energy (WIP)
Dual Energy, which will be available on Aquilion ONETM, Aquilion Premium and Aquilion PRIME (pending 510(k) clearance), uses two energy levels to increase the amount of information available from CT imaging. It can non-invasively help to visualize and characterize anatomy. Toshiba’s unique Dual Energy changes kV and mA during a single scan and deactivates the X-ray at the anterior section of the body to reduce overall radiation dose to sensitive areas.
Myocardial Perfusion (WIP)
With Toshiba’s Aquilion ONE, a combination of CTA and CT myocardial perfusion can be utilized to visualize blood flow and more precisely identify ischemia with less radiation than PET/CT and/or SPECT imaging. To validate this clinical application for CT, the multi-center, Toshiba-supported CORE320 trial completed enrollment in September and aims to compare the accuracy of CTA and CT myocardial perfusion to SPECT and Catheter Angiography.
Toshiba’s Body Perfusion is an application to evaluate perfusion of the target organ or target lesions with dynamic volume imaging of entire organs during contrast medium infusion. This can provide invaluable information in the diagnosis of disease and for assessing the effectiveness of treatment. Once combined with Toshiba’s AIDR 3D (pending 510(k) clearance) algorithm, Body Perfusion enables clinicians to perform body perfusion exams using lower dose, making it safer for the patient. It will be available for Aquilion ONE and Aquilion Premium.
“Technology advancements continue to take CT from anatomical to physiological, showing blood flow and function,” said Joseph Cooper, director, CT Business Unit, Toshiba. “Our new clinical CT applications enable clinicians to evaluate disease more easily, with the potential to dramatically improve patient care.”
With headquarters in Tustin, Calif., Toshiba America Medical Systems (TAMS) markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. For more information, visit the TAMS website at www.medical.toshiba.com.
Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultrasound, nuclear medicine, and MRI systems, as well as information systems for medical institutions. Toshiba Medical Systems Corporation has been providing medical products for over 80 years. Toshiba Medical Systems Corporation is a wholly owned subsidiary of Toshiba.
Toshiba is a diversified manufacturer and marketer of advanced electronic and electrical products, spanning digital products, such as LCD TVs, notebook PCs and hard disc drives; electronic devices and components, such as semiconductors; social infrastructure systems, including power generation systems, and home appliances. Toshiba was founded in 1875, and today operates a global network of more than 490 companies, with 203,000 employees worldwide and annual sales surpassing 6.3 trillion yen (US$77 billion).